Summary & Overview
HCPCS C9460: Injection, cangrelor, 1 mg
HCPCS Level II code C9460 denotes the billing unit for cangrelor as an injectable antiplatelet agent dosed per milligram (1 mg). Cangrelor is used for rapid, short-acting inhibition of platelet aggregation in acute procedural and peri-procedural cardiovascular settings, making clear coding essential for medication cost tracking and clinical billing compliance across acute care sites. Nationally, precise reporting of C9460 supports accurate reimbursement for hospitals and procedural centers that administer intravenous antiplatelet therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for cangrelor use, typical sites of service where C9460 is billed, and the payer landscape relevant to reimbursement and coverage. The publication outlines common billing considerations, expected service line placement, and where to look for policy updates that affect coverage and claims processing. Technical benchmarks, payer policy highlights, and practical coding notes are provided for billing professionals, revenue cycle staff, and clinicians involved in acute cardiovascular care.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code C9460 represents Injection, cangrelor, 1 mg. This code describes the billing unit for the intravenous antiplatelet agent cangrelor supplied and administered in a clinical setting.
Service Type: Intravenous injectable medication administration
Typical Site of Service: Hospital inpatient, outpatient procedural areas, and other acute care settings where intravenous antiplatelet therapy is provided
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult admitted to a hospital's cardiac catheterization laboratory or cardiac care unit for acute coronary syndrome undergoing percutaneous coronary intervention (PCI). The patient has an indication for a rapid-acting, short-duration intravenous P2Y12 platelet inhibitor to provide potent platelet inhibition during the procedure or when oral P2Y12 agents are contraindicated or cannot be absorbed (for example, ongoing vomiting or planned urgent surgery). The clinical workflow begins with assessment by the interventional cardiologist or attending physician, order entry for C9460 specifying the milligram dose of cangrelor required, verification of allergies and anticoagulation status by nursing, preparation of the drug by pharmacy or the procedural nurse, and intravenous bolus and infusion administration in the procedure suite or ICU. Monitoring includes continuous cardiac telemetry, frequent assessment of hemostasis at vascular access sites, and documentation of timing relative to other antithrombotic agents. Billing uses HCPCS Level II code C9460 reported per milligram of cangrelor administered, with appropriate modifiers added for billing circumstances such as distinct procedural events, provider status, or drug wastage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier/Default |